Tarnow

• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended
  2022-501540-15-00 5 2023-04-25 Atopic Dermatitis
• A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel … Ended
  2023-509243-27-00 4 2023-04-12 Moderate-to-Severe Uncontrolled Asthma
• Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68) Ended
  2024-517612-29-00 11 2023-02-14 acute heart failure
• A study to learn how well the drug EDP-938 works and how safe it is for non-hospitalized Adults with Acute Respiratory Syncytial Virus Infec … Ended
  2024-513861-38-00 4 2023-02-02 Respiratory syncytial virus (RSV)
• Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma Ended
  2024-510641-33-00 4 2023-01-17 Asthma
• A study to test the safety of MK-1654 and how well MK-1654 works in healthy infants Ended
  2022-500350-42-01 10 2022-11-07 Prevention of RSV
• Phase 3, Placebo-Controlled, Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Trial of a 6-Valent OspA-Based Lyme Disease … Ended
  2023-509105-72-00 5 2022-08-10 Active immunization against Lyme disease
• Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended
  2024-511263-28-00 6 2022-04-08 Hypercholesterolemia
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia. Ended
  2024-510696-38-00 5 2022-03-08 Severe Hypertriglyceridemia.
• An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects with Geographic Atrophy Secondary to … Ended
  2024-512945-18-00 5 2021-11-30 Geographic Atrophy Secondary to Age-Related Macular Degeneration
• A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended
  2022-500881-80-00 5 2021-10-29 Chronic Heart Failure With Reduced Ejection Fraction
• The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-510175-60-00 5 2021-06-16 Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis
• "A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with … Ended
  2023-505787-11-00 5 2021-04-29 Severe and inadequately controlled asthma
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok

Showing 97–111 of 111 trials